Manning Paul B — SEC insider filings
SEC reporting owner CIK 1494695. 55 insider filings on record with FilingPulse; latest filed 2026-10-02.
Transaction summary — filings shown
Covers the 50 most recent of 55 filings on record, filed 2020-09-30 to 2026-10-02. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 33 legs across 24 filings — 58,185,963 shares, $101,449,235 total (shares × price as filed on priced legs).
- Open-market sales (code S, non-derivative): 9 legs across 2 filings — 870,837 shares, $31,739,534 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 52.
- Largest priced transaction: purchase of 16,466,667 shares @ $0.90 ($14,820,000) in Taysha Gene Therapies, Inc., filed 2023-08-16.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Verrica Pharmaceuticals Inc. (VRCA) | Director, 10% owner | 7 | 9 legs · 32,799,224 sh · $39,889,554 | — | 11 |
| Liquidia Corp (LQDA) | Director | 16 | 4 legs · 1,206,977 sh · $7,499,993 | 9 legs · 870,837 sh · $31,739,534 | 11 |
| Taysha Gene Therapies, Inc. (TSHA) | 10% owner | 12 | 13 legs · 20,385,804 sh · $25,148,914 | — | 8 |
| Candel Therapeutics, Inc. (CADL) | Director | 14 | 6 legs · 3,481,458 sh · $23,910,774 | — | 17 |
| Acumen Pharmaceuticals, Inc. (ABOS) | 10% owner | 1 | 1 leg · 312,500 sh · $5,000,000 | — | 5 |
Insider filings — Manning Paul B
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-10-02 | 4 | Candel Therapeutics, Inc. (CADL) | Grant/award (A): 2,189 (derivative) @ $8.68 | EDGAR |
| 2026-07-01 | 4 | Candel Therapeutics, Inc. (CADL) | Grant/award (A): 2,199 (derivative) @ $8.64 | EDGAR |
| 2026-06-24 | 4 | Candel Therapeutics, Inc. (CADL) | Grant/award (A): 32,000 (derivative) @ $0 | EDGAR |
| 2026-06-18 | 4 | Liquidia Corp (LQDA) | Grant/award (A): 5,882 @ $0 | EDGAR |
| 2026-06-08 | 4 | Liquidia Corp (LQDA) | Sale (S): 11,513 @ $63.13 · Sale (S): 88,487 @ $64.28 · Sale (S): 19,125 @ $62.62 · Sale (S): 68,265 @ $63.83 · Sale (S): 12,610 @ $64.42 | EDGAR |
| 2026-04-02 | 4 | Candel Therapeutics, Inc. (CADL) | Grant/award (A): 4,618 (derivative) @ $4.11 | EDGAR |
| 2026-02-26 | 4 | Candel Therapeutics, Inc. (CADL) | Purchase (P): 550,458 @ $5.45 | EDGAR |
| 2026-02-12 | 4 | Liquidia Corp (LQDA) | Other (J): 55,116 @ $42.63 · Other (J): 55,116 @ $42.63 | EDGAR |
| 2025-11-25 | 4 | Verrica Pharmaceuticals Inc. (VRCA) | Purchase (P): 1,375,380 @ $4.24 · Purchase (P): 2,750,762 @ $4.24 · Purchase (P): 343,845 (derivative) · Purchase (P): 687,690 (derivative) | EDGAR |
| 2025-09-02 | 4 | Liquidia Corp (LQDA) | Sale (S): 154,337 @ $27.94 · Sale (S): 188,232 @ $27.62 · Sale (S): 254,038 @ $28.67 · Sale (S): 74,230 @ $29.14 | EDGAR |
| 2025-06-26 | 4 | Candel Therapeutics, Inc. (CADL) | Grant/award (A): 1,070,663 @ $4.67 | EDGAR |
| 2025-06-20 | 4 | Liquidia Corp (LQDA) | Grant/award (A): 18,396 @ $0 | EDGAR |
| 2025-06-18 | 4 | Candel Therapeutics, Inc. (CADL) | Grant/award (A): 14,240 (derivative) @ $0 | EDGAR |
| 2025-06-03 | 4 | Taysha Gene Therapies, Inc. (TSHA) | Purchase (P): 750,000 @ $2.75 | EDGAR |
| 2024-12-18 | 4 | Candel Therapeutics, Inc. (CADL) | Purchase (P): 500,000 @ $6 · Purchase (P): 750,000 @ $6 | EDGAR |
| 2024-11-26 | 4 | Verrica Pharmaceuticals Inc. (VRCA) | Purchase (P): 18,426,966 · Purchase (P): 4,494,382 · Gift (G): 450,000 @ $0 · Purchase (P): 9,213,483 (derivative) · Purchase (P): 9,213,483 (derivative) · Purchase (P): 2,247,191 (derivative) · +1 more | EDGAR |
| 2024-09-23 | 4 | Verrica Pharmaceuticals Inc. (VRCA) | Gift (G): 2,675,611.25 @ $0 · Gift (G): 891,870.41 @ $0 · Gift (G): 891,870.42 @ $0 · Gift (G): 891,870.42 @ $0 | EDGAR |
| 2024-09-16 | 4 | Liquidia Corp (LQDA) | Purchase (P): 337,078 @ $8.90 | EDGAR |
| 2024-07-01 | 4 | Taysha Gene Therapies, Inc. (TSHA) | Purchase (P): 1,333,333 @ $2.25 | EDGAR |
| 2024-06-27 | 4 | Candel Therapeutics, Inc. (CADL) | Grant/award (A): 14,240 (derivative) @ $0 | EDGAR |
| 2024-06-24 | 4 | Liquidia Corp (LQDA) | Grant/award (A): 20,359 @ $0 | EDGAR |
| 2023-12-18 | 4 | Liquidia Corp (LQDA) | Purchase (P): 279,330 @ $7.16 | EDGAR |
| 2023-11-20 | 4 | Taysha Gene Therapies, Inc. (TSHA) | Purchase (P): 100,000 @ $1.63 | EDGAR |
| 2023-08-16 | 4 | Taysha Gene Therapies, Inc. (TSHA) | Purchase (P): 16,466,667 @ $0.90 | EDGAR |
| 2023-07-24 | 4 | Verrica Pharmaceuticals Inc. (VRCA) | Purchase (P): 200,000 @ $5.02 | EDGAR |
| 2023-06-29 | 4 | Candel Therapeutics, Inc. (CADL) | Grant/award (A): 14,240 (derivative) @ $0 | EDGAR |
| 2023-06-21 | 4 | Liquidia Corp (LQDA) | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2022-11-02 | 4 | Taysha Gene Therapies, Inc. (TSHA) | Purchase (P): 1,500,000 @ $2 | EDGAR |
| 2022-10-17 | 4 | Candel Therapeutics, Inc. (CADL) | Grant/award (A): 14,240 (derivative) @ $0 | EDGAR |
| 2022-07-05 | 4 | Verrica Pharmaceuticals Inc. (VRCA) | Purchase (P): 4,761,904 @ $2.10 | EDGAR |
| 2022-06-22 | 4 | Liquidia Corp (LQDA) | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2022-06-22 | 4 | Taysha Gene Therapies, Inc. (TSHA) | Grant/award (A): 15,500 (derivative) @ $0 | EDGAR |
| 2022-04-20 | 4 | Liquidia Corp (LQDA) | Grant/award (A): 435,674 @ $0 | EDGAR |
| 2022-04-19 | 4 | Liquidia Corp (LQDA) | Purchase (P): 392,156 @ $5.10 | EDGAR |
| 2022-02-04 | 4 | Taysha Gene Therapies, Inc. (TSHA) | Purchase (P): 58,000 @ $7.77 · Purchase (P): 45,000 @ $7.77 · Purchase (P): 22,000 @ $7.77 · Purchase (P): 50,000 @ $7.84 · Purchase (P): 26,602 @ $7.84 | EDGAR |
| 2021-12-06 | 4 | Verrica Pharmaceuticals Inc. (VRCA) | Purchase (P): 30,023 @ $9.45 · Purchase (P): 19,977 @ $9.22 | EDGAR |
| 2021-11-29 | 4 | Taysha Gene Therapies, Inc. (TSHA) | Purchase (P): 2,202 @ $13.19 | EDGAR |
| 2021-11-24 | 4 | Taysha Gene Therapies, Inc. (TSHA) | Purchase (P): 20,000 @ $12.54 | EDGAR |
| 2021-09-01 | 4 | Liquidia Corp (LQDA) | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2021-08-04 | 4/A | Candel Therapeutics, Inc. (CADL) | Conversion (C): 679,158 · Conversion (C): 553,752 · Purchase (P): 1,625,000 @ $8 · Conversion (C): 1,669,303 (derivative) @ $0 · Conversion (C): 1,361,069 (derivative) @ $0 | EDGAR |
| 2021-08-02 | 4 | Candel Therapeutics, Inc. (CADL) | Conversion (C): 679,158 · Conversion (C): 553,752 · Conversion (C): 1,669,303 (derivative) @ $0 · Conversion (C): 1,361,069 (derivative) @ $0 | EDGAR |
| 2021-07-29 | 4 | Candel Therapeutics, Inc. (CADL) | Purchase (P): 36,000 @ $7.36 · Purchase (P): 20,000 @ $7.30 | EDGAR |
| 2021-07-08 | 4 | Acumen Pharmaceuticals, Inc. (ABOS) | Conversion (C): 2,950,484 · Purchase (P): 312,500 @ $16 · Conversion (C): 657,985 · Conversion (C): 1,634,515 (derivative) @ $0 · Conversion (C): 1,315,969 (derivative) @ $0 · Conversion (C): 657,985 (derivative) @ $0 | EDGAR |
| 2021-06-21 | 4 | Taysha Gene Therapies, Inc. (TSHA) | Grant/award (A): 15,500 (derivative) @ $0 | EDGAR |
| 2021-05-17 | 4 | Taysha Gene Therapies, Inc. (TSHA) | Purchase (P): 12,000 @ $20.98 | EDGAR |
| 2021-04-15 | 4 | Liquidia Corp (LQDA) | Purchase (P): 198,413 @ $2.52 | EDGAR |
| 2021-03-29 | 4 | Verrica Pharmaceuticals Inc. (VRCA) | Purchase (P): 739,830 @ $14.75 | EDGAR |
| 2021-03-26 | 4 | Liquidia Corp (LQDA) | Grant/award (A): 21,385 (derivative) @ $0 | EDGAR |
| 2020-11-19 | 4 | Liquidia Corp (LQDA) | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2020-09-30 | 4 | Taysha Gene Therapies, Inc. (TSHA) | Conversion (C): 3,275,205 · Conversion (C): 2,008,158 · Conversion (C): 11,944 · Conversion (C): 3,006,155 (derivative) @ $0 · Conversion (C): 1,843,193 (derivative) @ $0 · Conversion (C): 10,963 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-08-10 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1494695 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs